AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

The Effects of Immunonutrition Therapy on Locally Advanced Cervical Cancer Patients

RecruitingNAAges 18 Years - anyFemaleSHUANG ZHENG JIA, PhD
💬

In plain words

What the trial is, and whether it could suit you

The goal of this open-label randomized control trial is to study the effect of immunonutrition in locally advanced cervical cancer (LACC) with standard concurrent chemoradiotherapy. LACC patients undergoing radical synchronous chemoradiotherapy will be randomized into the experimental group receiving enteral immunonutrition therapy and the control group receiving standard enteral nutrition support.The main purpose it aims to answer are:1)Can immunonutrition therapy improve patients' dose-limiting toxicity(DLT) and DLT-free survival? 2)Can immunonutrition therapy improve patients' nutritional status and quality of life?

Sign in to get the eligibility rules as simple questions to take to your doctor.

📋 Eligibility rules (as published)
Inclusion Criteria: * Age ≥ 18 years; * Pathological histological diagnosis confirmed as cervical squamous cell carcinoma, adenocarcinoma, or adenosquamous carcinoma; * Confirmed as Locally Advanced Cervical Cancer (LACC) based on gynecological examination and imaging assessment; * Undergoing CCRT/RT treatment; * Patients are conscious, able to communicate without barriers, and able to answer questions. * diagnosed with malnutrition according to the GLIM criteria; Exclusion Criteria: * Patients who received neoadjuvant chemotherapy or immunotherapy before treatment; * Patients with concomitant other malignant tumors or a history of malignant tumors; * Patients with special pathological types of tumors such as cervical small cell carcinoma or neuroendocrine tumors; * Patients staged as Ⅳb according to the International Federation of Gynecology and Obstetrics(FIGO) 2018 staging system; * Patients with other severe chronic debilitating diseases, such as severe heart failure (New York Heart Association Class II-IV), severe liver damage (alanine aminotransferase ≥ 3 times the upper limit of normal), severe renal insufficiency (GFR \< 30 ml/min\*1.73 m²), etc.; * Eastern Cooperative Oncology Group(ECOG) performance status ≥ 2; * Presence of other contraindications to CCRT/RT.
💊

What it tests

  • enteral immunonutrition
  • standard oral enteral nutrition
📍

Where

1 site
Cancer Hospital, Chinese Academy of Medical Sciences
Beijing, China
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy